Development of clinical immunity to Plasmodium vivax following repeat controlled human malaria infection

This dataset contains details from a multi-cohort, repeat controlled human malaria infection (CHMI) study with Plasmodium vivax, and a heterologous rechallenge with P. falciparum. Malaria-naïve adults underwent P. vivax CHMI up to three times, at an interval of 5 to 20 months, by administration of red blood cells infected with the P. vivax PvW1 clone. In the final cohort of the study, a subset of participants underwent heterologous repeat CHMI with the P. falciparum 3D7 clone. Clinical parameters and the host response to infection were measured up to 3 months after each CHMI. The dataset includes parasite qPCR and multiplication rates (PMR), serum IgG anti-malarial antibody titres, solicited adverse events, alanine aminotransferase (ALT), albumin and haemoglobin (Hb) measurements as well as lymphocyte and platelet counts and a legendplex assay measuring inflammatory cytokines/chemokines as well as markers of coagulation and endothelium activation. This project was funded by funded by Horizon 2020 MultiViVax (Grant agreement ID: 733073).